Home/Pipeline/LBT-3627

LBT-3627

Parkinson's Disease

Phase 1Active

Key Facts

Indication

Parkinson's Disease

Phase

Phase 1

Status

Active

Company

Longevity Biotech

About Longevity Biotech

Longevity Biotech is a private, pre-revenue biotech firm founded in 2018 and based in San Francisco, operating in the RNA & Gene Therapy sector with a focus on neurodegeneration. The company is advancing a pipeline led by LBT-3627, which is in clinical trials for Parkinson's Disease, powered by its dual-platform approach of immune profiling and synthetic peptide engineering. It has secured non-dilutive funding from prestigious foundations and government agencies, positioning it to address a significant unmet medical need in a challenging therapeutic area. The company's strategy hinges on shifting the treatment paradigm from symptom management to disease modification through immune rebalancing.

View full company profile

Therapeutic Areas

Neurodegenerative Diseases Parkinson's Disease

Other Parkinson's Disease Drugs

Drug	Company	Phase	Status
NPT200-11	Neuropore Therapies	Phase 1	Partnered (UCB Pharma), status unclear
NUZ-001	Neurizon Therapeutics	Preclinical	Active
VXX-301	Vaxxinity	Preclinical	Pipeline
BAN2802	BioArctic	Phase 1	Active
CNM-Au8	Clene	Phase 2	Active
hpSC-Derived Neural/Dopaminergic Cells	International Stem Cell	Preclinical/Early Clinical	Inferred Active
SLS-004	Seelos Therapeutics	Preclinical	Research
SLS-007	Seelos Therapeutics	Preclinical	Research
Parkinson's Disease Portfolio (Platform-derived)	WD Pharmaceutical	Not Disclosed (Likely Preclinical/Early Clinical)	Active
UX-DA001	UniXell	Phase 1	Active, with trials ongoing in China and FDA IND cleared in U.S. (as of April 2025)
Parkinson's Disease Research	ProgenaBiome	Research	Active
A9 Dopaminergic Neuron Therapy	Trailhead Biosystems	Pre-clinical	Active